Masimo Receives Gates Foundation Grant to Develop Combined Pneumonia-Screening Device for High-Burden Settings

IRVINE, Calif.–(BUSINESS WIRE)–Masimo (NASDAQ:
MASI) announced today, in advance of World Pneumonia Day tomorrow, that
it has received a grant of $4.95 million from the Bill & Melinda Gates
Foundation (BMGF). The grant will support Masimo’s efforts to develop a
low-cost pulse oximeter for use in pneumonia screening in several
low-resource areas outside the U.S. While still in development, the
device will likely measure oxygen saturation (SpO2) and
respiration rate (RR) – two key parameters that would provide additional
information to clinicians when screening potential pneumonia cases in
high-burden settings. The grant will also support studying the clinical
use environment in such settings to ensure that the device is user
friendly and fit for its purpose. The grant may also support the
education materials to promote proper training and use of the device at
all literacy levels.

Pneumonia remains the single largest treatable infectious cause of death
in children worldwide, causing over 900,000 deaths each year among
children under 5 years of age.1 In a study funded by the BMGF
Diagnostics Modelling Consortium, the researchers concluded that in
settings where supplemental oxygen is available, the addition of pulse
oximetry to standard integrated management of child illness protocols
could reduce pneumonia mortality rates.2 More recently, the
World Health Organization (WHO) has sponsored an ongoing multi-country
study to further assess how to enhance community case management of
pneumonia treatment.3

Enhancing patient screening is critically important to reducing the
global burden of pneumonia. Moreover, enhanced screening may empower
healthcare providers by supporting informed decisions related to
pneumonia diagnosis and treatment, with the appropriate administration
of antibiotics and oxygen therapy when needed. Masimo and BMGF hope that
Masimo SET® Measure-through Motion and Low Perfusion™ pulse
oximetry technology can help better screen children in even the most
challenging conditions.

Rasa Izadnegahdar, Senior Program Officer on the Pneumonia Team at BMGF,
commented, “We are excited to partner with Masimo for the purpose of
improving screening for pneumonia to allow improved referral decisions
by health workers in low-resource settings. Evaluating a child for fast
breathing is the cornerstone of pneumonia assessment and combining this
with a reliable and effective approach to assessing oxygen saturation
can have significant impact in ensuring children with pneumonia receive
appropriate care. Our landscape review of pneumonia diagnostic aid
technologies has clearly demonstrated the poor performance of existing
diagnostic aids, particularly respiratory rate timers. Diagnostic aids
with improved sensitivity and specificity that are adapted and designed
for use by health workers and caregivers can make a significant impact
on pneumonia treatment. We look forward to working with Masimo to adapt
their precise and accurate technology to respond to the needs of health
workers, caregivers, and children in countries where pneumonia burden
and deaths remain unacceptably high.”

Masimo SET® Measure-through Motion and Low Perfusion™ pulse
oximetry is used to monitor millions of patients around the world. This
project demonstrates the company’s strong commitment to reducing the
unnecessarily high global burden of pneumonia by bringing its proven
patient screening and monitoring technology to the areas of the world
that need it most.

“We are gratified to be able to partner with BMGF, which recently joined
us in co-founding the United for Oxygen Alliance to increase
access to oxygen and pulse oximetry in Ethiopia, in supporting our
efforts to help fight pneumonia,” said Joe Kiani, Founder and CEO of
Masimo. “We hope to bring a much-needed screening tool to areas of the
world blighted by countless needless deaths that are due to an illness
considered low-risk in the developed world.”

@MasimoInnovates |
#Masimo

References

  1. Pneumonia Fact Sheet, World Health Organization (WHO), September 2016. http://www.who.int/mediacentre/factsheefts/fs331/en/.
  2. Floyd J et al. Evaluating the impact of pulse oximetry on childhood
    pneumonia mortality in resource-poor settings. Nature. 2015 Dec
    3;528(7580):S53-9.
  3. World Health Organization (WHO), 2016.

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® is estimated
to be used on more than 100 million patients in leading hospitals and
other healthcare settings around the world. In 2005, Masimo introduced
rainbow® Pulse CO-Oximetry technology, allowing noninvasive
and continuous monitoring of blood constituents that previously could
only be measured invasively, including total hemoglobin (SpHb®),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability
Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to
SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and
connectivity platform with the Masimo Open Connect™ (MOC-9™) interface.
Masimo is also taking an active leadership role in mHealth with products
such as the Radius-7™ wearable patient monitor and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and its
products may be found at www.masimo.com.
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.

Forward-Looking Statements

This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo pulse oximetry. These forward-looking statements
are based on current expectations about future events affecting us and
are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our
actual results to differ materially and adversely from those expressed
in our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to our
belief that Masimo’s unique noninvasive measurement technologies,
including Masimo pulse oximetry, contribute to positive clinical
outcomes and patient safety; risks related to our belief that Masimo
noninvasive medical breakthroughs provide comparable accuracy and unique
advantages; as well as other factors discussed in the “Risk Factors”
section of our most recent reports filed with the Securities and
Exchange Commission (“SEC”), which may be obtained for free at the SEC’s
website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today’s date. We do not undertake any obligation to update, amend or
clarify these statements or the “Risk Factors” contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws. —end—

Contacts

Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com